Recent Advances in Understanding of the Role of Synuclein Family Members in Health and Disease Volume II
Author Contributions
Funding
Conflicts of Interest
References
- Lavedan, C. The synuclein family. Genome Res. 1998, 8, 871–880. [Google Scholar] [CrossRef]
- Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2001, 2, 492–501. [Google Scholar] [CrossRef] [PubMed]
- Goedert, M.; Jakes, R.; Spillantini, M.G. The Synucleinopathies: Twenty Years On. J. Park. Dis. 2017, 7, S53–S71. [Google Scholar] [CrossRef] [PubMed]
- Henderson, M.X.; Trojanowski, J.Q.; Lee, V.M. alpha-Synuclein pathology in Parkinson’s disease and related alpha-synucleinopathies. Neurosci. Lett. 2019, 709, 134316. [Google Scholar] [CrossRef] [PubMed]
- Bougea, A. Synuclein in neurodegeneration. Adv. Clin. Chem. 2021, 103, 97–134. [Google Scholar]
- Kuo, G.; Kumbhar, R.; Blair, W.; Dawson, V.L.; Dawson, T.M.; Mao, X. Emerging targets of alpha-synuclein spreading in alpha-synucleinopathies: A review of mechanistic pathways and interventions. Mol. Neurodegener. 2025, 20, 10. [Google Scholar] [CrossRef]
- Norris, E.H.; Giasson, B.I.; Lee, V.M. Alpha-synuclein: Normal function and role in neurodegenerative diseases. Curr. Top. Dev. Biol. 2004, 60, 17–54. [Google Scholar]
- Benskey, M.J.; Perez, R.G.; Manfredsson, F.P. The contribution of alpha synuclein to neuronal survival and function-Implications for Parkinson’s disease. J. Neurochem. 2016, 137, 31–59. [Google Scholar] [CrossRef]
- Dolin, H.H.; Zhou, B.; Maitta, R.W. Alpha-Synuclein Dysregulation in Systemic Pathophysiology of Synucleinopathies. Front. Biosci. 2025, 30, 27178. [Google Scholar] [CrossRef]
- Zanotti, L.C.; Malizia, F.; Cesatti Laluce, N.; Avila, A.; Mamberto, M.; Anselmino, L.E.; Menacho-Marquez, M. Synuclein Proteins in Cancer Development and Progression. Biomolecules 2023, 13, 980. [Google Scholar] [CrossRef]
- Barba, L.; Paolini Paoletti, F.; Bellomo, G.; Gaetani, L.; Halbgebauer, S.; Oeckl, P.; Otto, M.; Parnetti, L. Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers. Mov. Disord. 2022, 37, 669–683. [Google Scholar] [CrossRef] [PubMed]
- Surguchov, A.; Surguchev, A. Synucleins: New Data on Misfolding, Aggregation and Role in Diseases. Biomedicines 2022, 10, 3241. [Google Scholar] [CrossRef] [PubMed]
- Zahra, F.T.; Kayani, H.; Noreen, S.; Noor, A.; Zafar, S. Synuclein Proteoforms: Role in Health and Disease. Mol. Neurobiol. 2025, 63, 87. [Google Scholar] [CrossRef] [PubMed]
- Dev, K.K.; Hofele, K.; Barbieri, S.; Buchman, V.L.; van der Putten, H. Part II: Alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 2003, 45, 14–44. [Google Scholar] [CrossRef]
- Hernandez, S.M.; Tikhonova, E.B.; Karamyshev, A.L. Protein-Protein Interactions in Alpha-Synuclein Biogenesis: New Potential Targets in Parkinson’s Disease. Front. Aging Neurosci. 2020, 12, 72. [Google Scholar] [CrossRef]
- Wang, J.; Dai, L.; Chen, S.; Zhang, Z.; Fang, X.; Zhang, Z. Protein-protein interactions regulating alpha-synuclein pathology. Trends Neurosci. 2024, 47, 209–226. [Google Scholar] [CrossRef]
- Pfefferkorn, C.M.; Jiang, Z.; Lee, J.C. Biophysics of alpha-synuclein membrane interactions. Biochim. Biophys. Acta 2012, 1818, 162–171. [Google Scholar] [CrossRef]
- Snead, D.; Eliezer, D. Alpha-synuclein function and dysfunction on cellular membranes. Exp. Neurobiol. 2014, 23, 292–313. [Google Scholar] [CrossRef]
- Kiechle, M.; Grozdanov, V.; Danzer, K.M. The Role of Lipids in the Initiation of alpha-Synuclein Misfolding. Front. Cell Dev. Biol. 2020, 8, 562241. [Google Scholar] [CrossRef]
- Bartels, T.; Ahlstrom, L.S.; Leftin, A.; Kamp, F.; Haass, C.; Brown, M.F.; Beyer, K. The N-terminus of the intrinsically disordered protein alpha-synuclein triggers membrane binding and helix folding. Biophys. J. 2010, 99, 2116–2124. [Google Scholar] [CrossRef]
- Ahanger, I.A.; Dar, T.A. Small molecule modulators of alpha-synuclein aggregation and toxicity: Pioneering an emerging arsenal against Parkinson’s disease. Ageing Res. Rev. 2024, 101, 102538. [Google Scholar] [CrossRef] [PubMed]
- Uversky, V.N.; Li, J.; Fink, A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson’s disease and heavy metal exposure. J. Biol. Chem. 2001, 276, 44284–44296. [Google Scholar] [CrossRef] [PubMed]
- Li, B.; Ge, P.; Murray, K.A.; Sheth, P.; Zhang, M.; Nair, G.; Sawaya, M.R.; Shin, W.S.; Boyer, D.R.; Ye, S.; et al. Cryo-EM of full-length alpha-synuclein reveals fibril polymorphs with a common structural kernel. Nat. Commun. 2018, 9, 3609. [Google Scholar] [CrossRef] [PubMed]
- Calabresi, P.; Mechelli, A.; Natale, G.; Volpicelli-Daley, L.; Di Lazzaro, G.; Ghiglieri, V. Alpha-synuclein in Parkinson’s disease and other synucleinopathies: From overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023, 14, 176. [Google Scholar] [CrossRef]
- Youdim, M.B. Iron in the brain: Implications for Parkinson’s and Alzheimer’s diseases. Mt. Sinai J. Med. 1988, 55, 97–101. [Google Scholar]
- Zecca, L.; Youdim, M.B.; Riederer, P.; Connor, J.R.; Crichton, R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004, 5, 863–873. [Google Scholar] [CrossRef]
- Tu, R.; Han, Z.; Zhang, H.; Jia, X.; Sun, T.; Liu, H.; Li, J.; Tang, M.; Wang, S. From pathogenesis to treatment: The emerging role of ferroptosis in Parkinson’s disease. Front. Immunol. 2025, 16, 1709561. [Google Scholar] [CrossRef]
- Huenchuguala, S.; Segura-Aguilar, J. On the Role of Iron in Idiopathic Parkinson’s Disease. Biomedicines 2023, 11, 3094. [Google Scholar] [CrossRef]
- Braak, H.; Del Tredici, K.; Rub, U.; de Vos, R.A.; Jansen Steur, E.N.; Braak, E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 2003, 24, 197–211. [Google Scholar] [CrossRef]
- Klingelhoefer, L.; Reichmann, H. Pathogenesis of Parkinson disease--the gut-brain axis and environmental factors. Nat. Rev. Neurol. 2015, 11, 625–636. [Google Scholar] [CrossRef]
- Klann, E.M.; Dissanayake, U.; Gurrala, A.; Farrer, M.; Wagle Shukla, A.; Ramirez-Zamora, A.; Mai, V.; Vedam-Mai, V. The Gut-Brain Axis and Its Relation to Parkinson’s Disease: A Review. Front. Aging Neurosci. 2021, 13, 782082. [Google Scholar] [CrossRef] [PubMed]
- Tan, A.H.; Lim, S.Y.; Lang, A.E. The microbiome-gut-brain axis in Parkinson disease-from basic research to the clinic. Nat. Rev. Neurol. 2022, 18, 476–495. [Google Scholar] [CrossRef] [PubMed]
- Gorecki, A.M.; Spencer, H.; Meloni, B.P.; Anderton, R.S. The Poly-Arginine Peptide R18D Interferes with the Internalisation of alpha-Synuclein Pre-Formed Fibrils in STC-1 Enteroendocrine Cells. Biomedicines 2023, 11, 2089. [Google Scholar] [CrossRef] [PubMed]
- Surguchov, A.; Emamzadeh, F.N.; Titova, M.; Surguchev, A.A. Controversial Properties of Amyloidogenic Proteins and Peptides: New Data in the COVID Era. Biomedicines 2023, 11, 1215. [Google Scholar] [CrossRef]
- Vorobyov, V.; Deev, A.; Chaprov, K.; Ustyugov, A.A.; Lysikova, E. Age-Related Modifications of Electroencephalogram Coherence in Mice Models of Alzheimer’s Disease and Amyotrophic Lateral Sclerosis. Biomedicines 2023, 11, 1151. [Google Scholar] [CrossRef]
- Visanji, N.P.; Brotchie, J.M.; Kalia, L.V.; Koprich, J.B.; Tandon, A.; Watts, J.C.; Lang, A.E. alpha-Synuclein-Based Animal Models of Parkinson’s Disease: Challenges and Opportunities in a New Era. Trends Neurosci. 2016, 39, 750–762. [Google Scholar] [CrossRef]
- Koprich, J.B.; Kalia, L.V.; Brotchie, J.M. Animal models of alpha-synucleinopathy for Parkinson disease drug development. Nat. Rev. Neurosci. 2017, 18, 515–529. [Google Scholar] [CrossRef]
- Vorobyov, V.; Deev, A.; Morozova, O.; Oganesyan, Z.; Krayushkina, A.M.; Ivanova, T.A.; Chaprov, K. Early Effects of Alpha-Synuclein Depletion by Pan-Neuronal Inactivation of Encoding Gene on Electroencephalogram Coherence between Different Brain Regions in Mice. Biomedicines 2023, 11, 3282. [Google Scholar] [CrossRef]
- Vorobyov, V.; Deev, A.; Chaprov, K.; Ninkina, N. Disruption of Electroencephalogram Coherence between Cortex/Striatum and Midbrain Dopaminergic Regions in the Knock-Out Mice with Combined Loss of Alpha, Beta, and Gamma Synucleins. Biomedicines 2024, 12, 881. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Ninkina, N.N.; Buchman, V.L. Recent Advances in Understanding of the Role of Synuclein Family Members in Health and Disease Volume II. Biomedicines 2026, 14, 67. https://doi.org/10.3390/biomedicines14010067
Ninkina NN, Buchman VL. Recent Advances in Understanding of the Role of Synuclein Family Members in Health and Disease Volume II. Biomedicines. 2026; 14(1):67. https://doi.org/10.3390/biomedicines14010067
Chicago/Turabian StyleNinkina, Natalia N., and Vladimir L. Buchman. 2026. "Recent Advances in Understanding of the Role of Synuclein Family Members in Health and Disease Volume II" Biomedicines 14, no. 1: 67. https://doi.org/10.3390/biomedicines14010067
APA StyleNinkina, N. N., & Buchman, V. L. (2026). Recent Advances in Understanding of the Role of Synuclein Family Members in Health and Disease Volume II. Biomedicines, 14(1), 67. https://doi.org/10.3390/biomedicines14010067
